38 related articles for article (PubMed ID: 18842333)
1. Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells.
Weng D; Song X; Xing H; Ma X; Xia X; Weng Y; Zhou J; Xu G; Meng L; Zhu T; Wang S; Ma D
Cancer Lett; 2009 Jan; 273(2):257-65. PubMed ID: 18842333
[TBL] [Abstract][Full Text] [Related]
2. The abnormal expression of chromosomal region maintenance 1 (CRM1)-survivin axis in ovarian cancer and its related mechanisms regulating proliferation and apoptosis of ovarian cancer cells.
Zhang J; Xu X; Chen Y; Guan X; Zhu H; Qi Y
Bioengineered; 2022 Jan; 13(1):624-633. PubMed ID: 34898375
[TBL] [Abstract][Full Text] [Related]
3. Sphingosine kinase-2 silencing modulates sensitivity of HT-29 human colorectal cancer cells to paclitaxel-induced cell death through altering apoptosis-related proteins.
Mu Y; Wang J; Li G
Chem Biol Drug Des; 2023 Aug; 102(2):255-261. PubMed ID: 36929215
[TBL] [Abstract][Full Text] [Related]
4. Targeted reversal of multidrug resistance in ovarian cancer cells using exosome‑encapsulated tetramethylpyrazine.
Zhao C; Qiu L; Wu D; Zhang M; Xia W; Lv H; Cheng L
Mol Med Rep; 2024 Feb; 29(2):. PubMed ID: 38099342
[TBL] [Abstract][Full Text] [Related]
5. Statement of Retraction: The abnormal expression of chromosomal region maintenance 1 (CRM1)-survivin axis in ovarian cancer and its related mechanisms regulating proliferation and apoptosis of ovarian cancer cells.
Bioengineered; 2024 Dec; 15(1):2299572. PubMed ID: 38376425
[No Abstract] [Full Text] [Related]
6. Corrigendum to "Cross-species analysis of transcriptome emphasizes a critical role of TNF-α in mediating MAP2K7/AKT2 signaling in zearalenone-induced apoptosis" [J Hazard Mater 459 (2023) 132226].
Zhang FL; Zhu KX; Wang JY; Zhang M; Yan JM; Liu QC; Zhang XY; Guo JC; Liu X; Sun QC; Ge W; Li L; Shen W
J Hazard Mater; 2024 Apr; 467():133716. PubMed ID: 38355376
[No Abstract] [Full Text] [Related]
7. Integrative microRNA and gene expression analysis identifies new epigenetically regulated microRNAs mediating taxane resistance in ovarian cancer.
Hassan MK; Waly AA; Elsayed W; Keshk S; Allam WR; El-Khamisy SF
Sci Rep; 2021 Jan; 11(1):562. PubMed ID: 33436648
[TBL] [Abstract][Full Text] [Related]
8. LHPP suppresses proliferation, migration, and invasion and promotes apoptosis in pancreatic cancer.
Wu F; Chen Y; Zhu J
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32186702
[TBL] [Abstract][Full Text] [Related]
9. Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo.
Chen S; Zhang Z; Zhang J
Drug Des Devel Ther; 2019; 13():1145-1153. PubMed ID: 31114158
[No Abstract] [Full Text] [Related]
10. Overexpressed miR-9 promotes tumor metastasis via targeting E-cadherin in serous ovarian cancer.
Zhou B; Xu H; Xia M; Sun C; Li N; Guo E; Guo L; Shan W; Lu H; Wu Y; Li Y; Yang D; Weng D; Meng L; Hu J; Ma D; Chen G; Li K
Front Med; 2017 Jun; 11(2):214-222. PubMed ID: 28470508
[TBL] [Abstract][Full Text] [Related]
11. A multi-shRNA vector enhances the silencing efficiency of exogenous and endogenous genes in human cells.
Weng Y; Shi Y; Xia X; Zhou W; Wang H; Wang C
Oncol Lett; 2017 Mar; 13(3):1553-1562. PubMed ID: 28454290
[TBL] [Abstract][Full Text] [Related]
12. let-7b and let-7c are determinants of intrinsic chemoresistance in renal cell carcinoma.
Peng J; Mo R; Ma J; Fan J
World J Surg Oncol; 2015 May; 13():175. PubMed ID: 25951903
[TBL] [Abstract][Full Text] [Related]
13. Aplysin sensitizes cancer cells to TRAIL by suppressing P38 MAPK/survivin pathway.
Liu J; Ma L; Wu N; Liu G; Zheng L; Lin X
Mar Drugs; 2014 Sep; 12(9):5072-88. PubMed ID: 25257790
[TBL] [Abstract][Full Text] [Related]
14. Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer.
Chen P; Luo S; Wen YJ; Li YH; Li J; Wang YS; Du LC; Zhang P; Tang J; Yang DB; Hu HZ; Zhao X; Wei YQ
Cancer Sci; 2014 Nov; 105(11):1393-401. PubMed ID: 25230206
[TBL] [Abstract][Full Text] [Related]
15. BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin.
Paul BT; Blanchard Z; Ridgway M; ElShamy WM
Oncogene; 2015 Jun; 34(23):3036-52. PubMed ID: 25132263
[TBL] [Abstract][Full Text] [Related]
16. Oncogenes associated with drug resistance in ovarian cancer.
Liu X; Gao Y; Lu Y; Zhang J; Li L; Yin F
J Cancer Res Clin Oncol; 2015 Mar; 141(3):381-95. PubMed ID: 24997551
[TBL] [Abstract][Full Text] [Related]
17. Diverse mechanisms of AKT pathway activation in human malignancy.
Cheung M; Testa JR
Curr Cancer Drug Targets; 2013 Mar; 13(3):234-44. PubMed ID: 23297823
[TBL] [Abstract][Full Text] [Related]
18. Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer.
Iida K; Zheng R; Shen R; Nanus DM
Int J Oncol; 2012 Oct; 41(4):1192-8. PubMed ID: 22895534
[TBL] [Abstract][Full Text] [Related]
19. The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines.
Glienke W; Maute L; Wicht J; Bergmann L
Tumour Biol; 2012 Jun; 33(3):757-65. PubMed ID: 22170433
[TBL] [Abstract][Full Text] [Related]
20. Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer.
Xia X; Ma Q; Li X; Ji T; Chen P; Xu H; Li K; Fang Y; Weng D; Weng Y; Liao S; Han Z; Liu R; Zhu T; Wang S; Xu G; Meng L; Zhou J; Ma D
BMC Cancer; 2011 Sep; 11():399. PubMed ID: 21933447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
